Literature DB >> 8146299

Inhibition of topoisomerase II alpha activity in CHO K1 cells by 2-[(aminopropyl)amino]ethanethiol (WR-1065).

D J Grdina1, A Constantinou, N Shigematsu, J S Murley.   

Abstract

The aminothiol 2-[(aminopropyl)amino]ethanethiol (WR-1065) is the active thiol of the clinically studied radioprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). WR-1065 is an effective radiation protector when it is administered 30 min prior to exposure of Chinese hamster ovary K1 cells to radiation (i.e., a dose modification factor of 1.4) at a concentration of 4 mM. Under these exposure conditions, topoisomerase (Topo) I and II alpha activities and associated protein contents were measured in cells of the K1 cell line using the DNA relaxation assay, the P4 unknotting assay and immunoblotting, respectively. WR-1065 was ineffective in modifying Topo I activity, but it did reduce Topo II alpha activity by an average of 50%. The magnitude of Topo II alpha protein content, however, was not affected by these exposure conditions. The effects on the cell cycle were monitored by the method of flow cytometry. Exposure of cells to 4 mM WR-1065 for up to 6 h resulted in a build-up of cells in the G2/M-phase compartment. However, under these conditions and in contrast to Topo II inhibitors used in chemotherapy, WR-1065 is an effective radioprotective agent capable of protecting against both radiation-induced cell lethality and mutagenesis. One of several mechanisms of action attributed to aminothiol compounds such as WR-1065 has been their ability to affect endogenous enzymatic reactions involved in DNA synthesis and repair and progression of cells through the phases of the cell cycle. These results are consistent with such a proposed mechanism and demonstrate in particular a modifying effect by WR-1065 on Topo II, which is involved in DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8146299

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  8 in total

1.  ROS-scavenger and radioprotective efficacy of the new PrC-210 aminothiol.

Authors:  Daniel D Peebles; Cheryl M Soref; Richard R Copp; Allen L Thunberg; William E Fahl
Journal:  Radiat Res       Date:  2012-06-14       Impact factor: 2.841

2.  Potentiation of the antitumor effect of Merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B.

Authors:  Ichiro Tsujino; Kiyoko Miyagi; Reynée W Sampson; Fritz Sieber
Journal:  Photochem Photobiol       Date:  2006 Mar-Apr       Impact factor: 3.421

3.  Amifostine metabolite WR-1065 disrupts homologous recombination in mammalian cells.

Authors:  Jaroslaw Dziegielewski; Wilfried Goetz; Jeffrey S Murley; David J Grdina; William F Morgan; Janet E Baulch
Journal:  Radiat Res       Date:  2010-02       Impact factor: 2.841

4.  Effects of thiols on topoisomerase-II alpha activity and cell cycle progression.

Authors:  D J Grdina; J S Murley; J C Roberts
Journal:  Cell Prolif       Date:  1998 Oct-Dec       Impact factor: 6.831

5.  Modulation of chromatin organization by RH-3, a preparation of Hippophae rhamnoides, a possible role in radioprotection.

Authors:  I Prem Kumar; Samanta Namita; H C Goel
Journal:  Mol Cell Biochem       Date:  2002-09       Impact factor: 3.396

Review 6.  Heavy ions, radioprotectors and genomic instability: implications for human space exploration.

Authors:  Jaroslaw Dziegielewski; Wilfried Goetz; Janet E Baulch
Journal:  Radiat Environ Biophys       Date:  2009-12-25       Impact factor: 1.925

7.  p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection.

Authors:  E J Lee; M Gerhold; M W Palmer; R D Christen
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

8.  Amifostine reduces the seminiferous epithelium damage in doxorubicin-treated prepubertal rats without improving the fertility status.

Authors:  Vanessa Vendramini; Estela Sasso-Cerri; Sandra M Miraglia
Journal:  Reprod Biol Endocrinol       Date:  2010-01-10       Impact factor: 5.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.